SLC5A2 and type 2 diabetes mellitus: As a result of their insulin-independent mechanism of action, SGLT-2 inhibitors can be used for monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with type 2 diabetes [1,2].